Prevalence of PIK3CA mutations and the SNP rs17849079 in Arab breast cancer patients

Cancer Biology and Therapy

Volumn 14, Issue 10, 2013, Pages 888-896

  Karakas, Bedri ^a   Colak, Dilek ^a   Kaya, Namik ^a   Ghebeh, Hazem ^a   Al Qasem, Abeer ^a   Hendrayani, Fawziah ^a   Toulimat, Mohamed ^a   Al Tweigeri, Taher ^a   Park, Ben Ho ^b   Aboussekhra, Abdelilah ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Breast cancer; CAF; Mutation; PI3K; PIK3CA; SNP

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROGESTERONE RECEPTOR;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARAB; ARTICLE; BREAST CARCINOMA; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; EXON; FEMALE; FIBROBLAST; GENE; GENE FREQUENCY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PIK3CA GENE; PREVALENCE; SAUDI ARABIA; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; SURVIVAL RATE;

BREAST CANCER; CAF; MUTATION; PI3K; PIK3CA; SNP;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MUTATION, MISSENSE; PHOSPHATIDYLINOSITOL 3-KINASES; POLYMORPHISM, SINGLE NUCLEOTIDE; PREVALENCE; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SAUDI ARABIA; TUMOR CELLS, CULTURED; YOUNG ADULT;

EID: 84885192147     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.25945     Document Type: Article

References (48)

1. Garcia M, Jemal A, Ward E, Center MM, Hao Y. Global Cancer Facts and Figures 2007. American Cancer Society 2007.
2. Al-Eid HS. Cancer Incidence Report: Saudi Arabia. National Cancer Registry 2004.
3. Porter P. "Westernizing" women's risks? Breast cancer in lower-income countries. N Engl J Med 2008; 358:213-6; PMID:18199859; http://dx.doi.org/10.1056/NEJMp0708307
4. Deramaudt T, Rustgi AK. Mutant KRAS in the initiation of pancreatic cancer. Biochim Biophys Acta 2005; 1756:97-101; PMID:16169155 (Pubitemid 41773136)
5. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61:759-67; PMID:2188735; http://dx.doi.org/10.1016/0092-8674(90) 90186-I
6. Esteller M. Epigenetics in cancer. N Engl J Med 2008; 358:1148-59; PMID:18337604; http://dx.doi. org/10.1056/NEJMra072067
7. Warnecke PM, Bestor TH. Cytosine methyla-tion and human cancer. Curr Opin Oncol 2000; 12:68-73; PMID:10687732; http://dx.doi. org/10.1097/00001622- 200001000-00012
8. Orimo A, Weinberg RA. Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle 2006; 5:1597-601; PMID:16880743; http://dx.doi. org/10.4161/cc.5.15.3112 (Pubitemid 44285243)
9. Eng C, Leone G, Orloff MS, Ostrowski MC. Genomic alterations in tumor stroma. Cancer Res 2009; 69:6759-64; PMID:19706759; http://dx.doi. org/10.1158/0008-5472.CAN-09-0985
10. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002; 296:1655-7; PMID:12040186; http://dx.doi.org/10.1126/science.296.5573.1655 (Pubitemid 34579158)
11. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006; 7:606-19; PMID:16847462; http://dx.doi.org/10.1038/nrg1879 (Pubitemid 44100518)
12. Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007; 318:1108-13; PMID:17932254; http://dx.doi.org/10.1126/science.1145720 (Pubitemid 350134889)
13. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304:554-554; PMID:15016963; http://dx.doi.org/10.1126/sci-ence.1096502
14. Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, Konishi H, Karakas B, Blair BG, Lin C, et al. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 2004; 3:772-5; PMID:15254419; http://dx.doi.org/10.4161/cbt.3.8.994 (Pubitemid 41351083)
15. Karakas B, Bachman KE, Park BH. Mutation of the PIK3CA oncogene in human cancers. Br J Cancer 2006; 94:455-9; PMID:16449998; http://dx.doi. org/10.1038/sj.bjc.6602970 (Pubitemid 43289745)
16. Samuels Y, Diaz LA Jr., Schmidt-Kittler O, Cummins JM, Delong L, Cheong I, Rago C, Huso DL, Lengauer C, Kinzler KW, et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 2005; 7:561-73; PMID:15950905; http://dx.doi. org/10.1016/j.ccr.2005.05.014 (Pubitemid 40799249)
17. Gustin J P, Karakas B, Weiss MB, Abukhdeir AM, Lauring J, Garay J P, Cosgrove D, Tamaki A, Konishi H, Konishi Y, et al. Knockin of mutant PIK3CA activates multiple oncogenic pathways. Proc Natl Acad Sci USA 2009; 106:2835-40; PMID:19196980; http://dx.doi. org/10.1073/pnas.0813351106
18. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009; 9:550-62; PMID:19629070; http://dx.doi.org/10.1038/nrc2664
19. Allison M. Is personalized medicine finally arriving? Nat Biotechnol 2008; 26:509-17; PMID:18464779; http://dx.doi.org/10.1038/nbt0508-509 (Pubitemid 351668034)
20. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j. cell.2011.02.013
21. Vogelstein B, Kinzler K W. Cancer genes and the pathways they control. Nat Med 2004; 10:789-99; PMID:15286780; http://dx.doi.org/10.1038/nm1087 (Pubitemid 39070849)
22. http://www.sanger.ac.uk/genetics/CGP/cosmic/
23. Di Nicolantonio F, Arena S, Tabernero J, Grosso S, Molinari F, Macarulla T, Russo M, Cancelliere C, Zecchin D, Mazzucchelli L, et al. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest 2010; 120:2858-66; PMID:20664172; http://dx.doi.org/10.1172/JCI37539
24. Mohseni M, Park BH. PIK3CA and KRAS mutations predict for response to everolimus therapy: now that's RAD001. J Clin Invest 2010; 120:2655-8; PMID:20664174; http://dx.doi.org/10.1172/JCI44026
25. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009; 8:627-44; PMID:19644473; http://dx.doi.org/10.1038/nrd2926
26. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010; 28:1075-83; PMID:20085938; http://dx.doi.org/10.1200/JCO.2009.25.3641
27. Maira S-M, Finan P, Garcia-Echeverria C. From the bench to the bed side: PI3K pathway inhibitors in clinical development. Curr Top Microbiol Immunol 2010; 347:209-39; PMID:20582534; http://dx.doi. org/10.1007/82-2010-60
28. Chavez-MacGregor M, Gonzalez-Angulo AM. Everolimus in the treatment of hormone receptor-positive breast cancer. Expert Opin Investig Drugs 2012; 21:1835-43; PMID:22994502; http://dx.doi.org/10.1517/13543784.2012.726218
29. Kalinsky K, Jacks LM, Heguy A, Patil S, Drobnjak M, Bhanot UK, Hedvat CV, Traina TA, Solit D, Gerald W, et al. PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res 2009; 15:5049-59; PMID:19671852; http://dx.doi. org/10.1158/1078-0432.CCR-09-0632
30. Barbareschi M, Buttitta F, Felicioni L, Cotrupi S, Barassi F, Del Grammastro M, Ferro A, Dalla Palma P, Galligioni E, Marchetti A. Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin Cancer Res 2007; 13:6064-9; PMID:17947469; http://dx.doi. org/10.1158/1078-0432.CCR-07-0266 (Pubitemid 350075063)
31. Maruyama N, Miyoshi Y, Taguchi T, Tamaki Y, Monden M, Noguchi S. Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women. Clin Cancer Res 2007; 13:408-14; PMID:17202311; http://dx.doi.org/10. 1158/1078-0432.CCR-06-0267 (Pubitemid 46225343)
32. Li SY, Rong M, Grieu F, Iacopetta B. PIK3CA mutations in breast cancer are associated with poor outcome. Breast Cancer Res Treat 2006; 96:91-5; PMID:16317585; http://dx.doi.org/10.1007/s10549-005-9048-0
33. Lerma E, Catasus L, Gallardo A, Peiro G, Alonso C, Aranda I, Barnadas A, Prat J. Exon 20 PIK3CA mutations decreases survival in aggressive (HER-2 positive) breast carcinomas. Virchows Arch 2008; 453:133-9; PMID:18679714; http://dx.doi.org/10.1007/s00428-008-0643-4
34. Loi S, Haibe-Kains B, Majjaj S, Lallemand F, Durbecq V, Larsimont D, Gonzalez-Angulo AM, Pusztai L, Symmans W F, Bardelli A, et al. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci USA 2010; 107:10208-13; PMID:20479250; http://dx.doi. org/10.1073/pnas.0907011107
35. Michelucci A, Di Cristofano C, Lami A, Collecchi P, Caligo A, Decarli N, Leopizzi M, Aretini P, Bertacca G, Porta R P, et al. PIK3CA in breast carcinoma: a muta-tional analysis of sporadic and hereditary cases. Diagn Mol Pathol 2009; 18:200-5; PMID:19861897; http://dx.doi.org/10.1097/PDM.0b013e31818e5fa4
36. Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, Yu JS, Malmström PO, Mansukhani M, Enoksson J, et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005; 65:2554-9; PMID:15805248; http://dx.doi.org/10.1158/0008-5472-CAN-04-3913 (Pubitemid 40490050)
37. Abubaker J, Bavi P, Al-Harbi S, Ibrahim M, Siraj AK, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F, et al. Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population. Oncogene 2008; 27:3539-45; PMID:18193083; http://dx.doi.org/10.1038/ sj.onc.1211013 (Pubitemid 351793794)
38. Abubaker J, Bavi P, Al-Haqawi W, Jehan Z, Munkarah A, Uddin S, Al-Kuraya KS. PIK3CA alterations in Middle Eastern ovarian cancers. Mol Cancer 2009; 8:51; PMID:19638206; http://dx.doi. org/10.1186/1476-4598-8-51
39. Cohen Y, Merhavi-Shoham E, Avraham-Lubin BCR, Savetsky M, Frenkel S, Pe'er J, Goldenberg-Cohen N. PI3K/Akt pathway mutations in retinoblasto-ma. Invest Ophthalmol Vis Sci 2009; 50:5054-6; PMID:19420344; http://dx.doi.org/10. 1167/iovs.09-3617
40. Goff LA, Davila J, Swerdel MR, Moore JC, Cohen RI, Wu H, Sun YE, Hart R P. Ago2 immunopre-cipitation identifies predicted microRNAs in human embryonic stem cells and neural precursors. PLoS One 2009; 4:e7192; PMID:19784364; http://dx.doi. org/10.1371/journal.pone.0007192
41. miRBase. http://www.mirbase.org/search.shtml
42. Campbell I, Qiu W, Haviv I. Genetic changes in tumour microenvironments. J Pathol 2011; 223:450-8; PMID:21294119; http://dx.doi.org/10.1002/path.2842
43. Orimo A, Weinberg RA. Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle 2006; 5:1597-601; PMID:16880743; http://dx.doi. org/10.4161/cc.5.15.3112 (Pubitemid 44285243)
44. Kurose K, Gilley K, Matsumoto S, Watson PH, Zhou X-P, Eng C. Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nat Genet 2002; 32:355-7; PMID:12379854; http://dx.doi.org/ 10.1038/ng1013 (Pubitemid 35266108)
45. Patocs A, Zhang L, Xu Y, Weber F, Caldes T, Mutter GL, Platzer P, Eng C. Breast-cancer stromal cells with TP53 mutations and nodal metastases. N Engl J Med 2007; 357:2543-51; PMID:18094375; http://dx.doi. org/10.1056/NEJMoa071825 (Pubitemid 350294221)
46. Qiu W, Hu M, Sridhar A, Opeskin K, Fox S, Shipitsin M, Trivett M, Thompson ER, Ramakrishna M, Gorringe KL, et al. No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas. Nat Genet 2008; 40:650-5; PMID:18408720; http://dx.doi. org/10.1038/ng.117 (Pubitemid 351601206)
47. Hosein AN, Wu M, Arcand SL, Lavallée S, Hébert J, Tonin PN, Basik M. Breast carcinoma-associated fibroblasts rarely contain p53 mutations or chromosomal aberrations. Cancer Res 2010; 70:5770-7; PMID:20570891; http://dx.doi.org/10.1158/0008-5472.CAN-10-0673
48. Hawsawi NM, Ghebeh H, Hendrayani S-F, Tulbah A, Al-Eid M, Al-Tweigeri T, Ajarim D, Alaiya A, Dermime S, Aboussekhra A. Breast carcinoma-associated fibroblasts and their counterparts display neo-plastic-specific changes. Cancer Res 2008; 68:2717-25; PMID:18413739; http://dx.doi.org/10.1158/0008-5472.CAN-08- 0192 (Pubitemid 351556269)